-+ 0.00%
-+ 0.00%
-+ 0.00%
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
Share
Listen to the news

SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to discuss second quarter 2026 financial results and provide a general business update.

BioMarin Pharmaceutical logo

Dial-in Number 

U.S. / Canada Dial-in Number: 800-715-9871

International Dial-in Number: 646-307-1963

Conference Call ID: 3551298 

U.S. / Canada Replay Dial-in Number: 800-770-2030

International Replay Dial-in Number: 609-800-9909

Playback ID: 3551298 

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com

Contacts:







Investors

Media

Traci McCarty

Marni Kottle

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(650) 374-2803

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-second-quarter-2026-financial-results-conference-call-and-webcast-on-thursday-august-6-2026-at-430pm-et-302838363.html

SOURCE BioMarin Pharmaceutical Inc.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending